

Please amend the claims as follows:

1-28. (Cancelled)

29. (Currently Amended) A method of inducing activation of dendritic cells comprising administering a composition to a mammal comprising [[a]] at least one polynucleotide [[or derivative thereof]] and at least one [[non-modified]] polyoxyethylene-polyoxypropylene block copolymer, wherein an antigen is expressed and an adjuvant is expressed from the at least one polynucleotide thereby activating dendritic cells.

30. (Currently Amended) The method of claim 29 wherein the adjuvant is a cytokine and the composition comprises [[block copolymers comprise]] at least PLURONIC F127 and L61.

31. (Currently Amended) The method of claim 30 wherein the adjuvant is selected from the group consisting essentially of an interleukin, interleukin-12, Flt3 ligand, GM-CSF, and CD40 ligand; and the block copolymer is present in amounts insufficient for gel formation.

32. (Currently Amended) A method of inducing activation of dendritic cells comprising administering a composition to a mammal comprising [[a]] at least one polynucleotide [[or derivative thereof]] and at least one [[non-modified]] polyoxyethylene-polyoxypropylene block copolymer, wherein the composition forms a molecular solution or colloidal dispersion, wherein the at least one polynucleotide comprises a CMV promoter or a NF- κ B-sensitive element, and wherein an antigen is expressed and an adjuvant is expressed from the at least one polynucleotide thereby activating dendritic cells.

33. (Currently Amended) The method of claim 32 wherein the [[block copolymers are]] at least one polyoxyethylene-polyoxypropylene block copolymer comprises PLURONIC F127 and L61.

34. (Currently Amended) A method of increasing an immune response comprising administering a composition comprising [[a]] at least one polynucleotide [[, viral vector, or

polynucleotide derivative thereof]] and at least one [[non-modified]] polyoxyethylene-polyoxypropylene block copolymer to a mammal, wherein an antigen is expressed and an adjuvant is expressed from the at least one polynucleotide thereby inducing an immune response.

35. (Currently Amended) The method of claim 34 wherein the composition comprises [[block copolymers comprise]] at least PLURONIC F127 and L61.

36. (Original) The method of claim 34 wherein the composition is administered orally, topically, rectally, vaginally, parenterally, intramuscularly, intradermally, subcutaneously, intraparietally, or intravenously.

37. (Currently Amended) A method of increasing an immune response comprising intramuscularly administering a composition comprising [[a]] at least one polynucleotide [[, viral vector, or polynucleotide derivative thereof]] and at least one [[non-modified]] polyoxyethylene-polyoxypropylene block copolymer to a mammal, wherein an antigen is expressed and an adjuvant is expressed from the at least one polynucleotide thereby increasing an immune response.

38. (Currently Amended) The method of claim 37 wherein the composition comprises [[block copolymers comprise]] at least PLURONIC F127 and L61.

39. (Original) The method of claim 37 wherein said composition is administered to at least one of smooth, skeletal, and cardiac muscles.

40. (Currently Amended) A method of increasing an immune response comprising intradermally administering a composition comprising [[a]] at least one polynucleotide [[, viral vector, or polynucleotide derivative thereof]] and at least one [[non-modified]] polyoxyethylene-polyoxypropylene block copolymer to a mammal, wherein an antigen is expressed and an adjuvant is expressed from the at least one polynucleotide thereby increasing an immune response.

41-69. (Cancelled)

70. (Currently Amended) A method of inducing the activation of dendritic cells comprising administering a composition to a mammal comprising at least one [[non-modified]] polyoxyethylene-polyoxypropylene block copolymer and [[a]] at least one polynucleotide [[or derivative thereof]], wherein the block copolymer is present in amounts insufficient for gel formation and wherein an antigen is expressed and an adjuvant is expressed from the at least one polynucleotide.

71. (Currently Amended) The method of claim 70 wherein the composition comprises [[block copolymers comprise]] at least PLURONIC F127 and L61.

72. (Currently Amended) A method of inducing activation of dendritic cells comprising administering a composition to a mammal comprising at least one [[non-modified]] polyoxyethylene-polyoxypropylene block copolymer and [[a]] at least one polynucleotide [[or derivative thereof]] wherein the composition forms a molecular solution or colloidal dispersion, and wherein an antigen is expressed and an adjuvant is expressed from the at least one polynucleotide.

73. (Original) The method of claim 72 wherein the block copolymers are PLURONIC F127 and L61.

74. (Previously Amended) A method of increasing an immune response comprising administering the composition according to claim 72 to a mammal.

75. (Original) The method of claim 72 wherein the composition is administered orally, topically, rectally, vaginally, parenterally, intramuscularly, intradermally, subcutaneously, intraperitoneally, or intravenously.

76. (Original) The method of claim 72 wherein said composition is administered to at least one of smooth, skeletal, and cardiac muscles.

77. (Currently Amended) A method of ~~[[improving]]~~ increasing the immune response of a mammal comprising intradermally administering ~~[[the composition according to claim 34]]~~ a composition comprising at least one polynucleotide and at least one polyoxyethylene-polyoxypropylene block copolymer, wherein an antigen is expressed and an adjuvant is expressed from the at least one polynucleotide.